

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. **(Currently Amended)** A capsule preparation, which comprises a capsule shell and contained inside the capsule shell a medicine unstable to moisture, wherein the capsule shell is stable in a low moisture state and has pH-independent disintegration properties, and provided that the capsule shell excludes hard gelatin and/or a cellulose derivative as a main component of the capsule shell.

2. **(Original)** The capsule preparation according to claim 1, which is stable in a low moisture state which is less or equal to relative humidity of about 35%.

3. **(Currently Amended)** The capsule preparation according to claim 1, wherein the main component of the capsule shell is a gelatin containing polyethylene glycol.


4. **(Currently Amended)** The capsule preparation according to claim 1, wherein the main component of the capsule shell is a water-soluble polysaccharide.

5. **(Currently Amended)** The capsule preparation according to claim 1, wherein the main component of the capsule shell is pullulan.

6. **(Original)** The capsule preparation according to claim 1, which combines a capsule shell comprising gelatin containing polyethylene glycol as the main component and a capsule shell comprising pullulan as the main component.

7. **(Original)** The capsule preparation according to claim 1, wherein the medicine unstable to moisture is a proton pump inhibitor (PPI).

8. **(Original)** The capsule preparation according to claim 7, wherein the PPI is an imidazole type compound represented by the formula (I'):



wherein the ring C' is an optionally substituted benzene ring or an optionally substituted aromatic mono-heterocyclic ring, R⁰ is a hydrogen atom, an optionally substituted aralkyl group, an acyl group or an acyloxy group, each of R¹, R² and R³ which may be the same or different, and is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, or an optionally substituted amino group, and Y is a nitrogen atom or CH, or an optically active isomer thereof or a salt thereof.

9. **(Original)** The capsule preparation according to claim 8, wherein C' is an optionally substituted benzene ring.

10. **(Original)** The capsule preparation according to claim 7, wherein the PPI is lansoprazole, omeprazole, rabeprazole, pantoprazole, tenatoprazole, or an optically active isomer thereof or a salt thereof.

11. **(Original)** The capsule preparation according to claim 7, wherein the PPI is lansoprazole.

12. **(Previously Presented)** The capsule preparation according to claim 7, wherein the PPI is the R-isomer of lansoprazole.

13. **(Original)** The capsule preparation according to claim 1, wherein the medicine unstable to moisture is a prodrug of PPI.

14. **(Original)** The capsule preparation according to claim 1, wherein the content in the capsule is a powdered medicine.

15. **(Original)** The capsule preparation according to claim 1, wherein the content in the capsule is fine granules optionally coated, granules optionally coated and/or tablets optionally coated.

16. **(Original)** The capsule preparation according to claim 15, which contains at least two solid preparations selected from fine granules, granules and tablets in combination.

17. **(Original)** The capsule preparation according to claim 16, wherein the combined solid preparations have different medicine release properties.

18. **(Original)** The capsule preparation according to claim 16, wherein at least one of the combined solid preparations has a coating layer.

19. **(Original)** The capsule preparation according to claim 18, wherein the coating layer is an enteric coating layer.

20. **(Original)** The capsule preparation according to claim 18, wherein the coating layer contains a controlled-release coating layer.

21. **(Previously Presented)** The capsule preparation according to claim 20, wherein the controlled-release coating layer is a coating layer within a range of pH 6.0 to pH 7.5.

22. **(Original)** The capsule preparation according to claim 21, wherein the controlled-release coating layer is a diffusion-control type controlled-release film.

23. **(Original)** The capsule preparation according to claim 21, wherein the controlled-release coating layer is a time release type controlled-release coating film.

24. **(Original)** The capsule preparation according to claim 16, which contains fine granules, granules or tablets having an enteric coating layer in combination with fine granules, granules or tablets having a controlled-release coating layer.